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Since Advance Online Publication, Fig. 2G has been corrected to show the correct (ETD) fragmentation spectrum that
was used to map the TAB1 O-GlcNAc site and as referred to in the ﬁgure legend.
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Transforming growth factor (TGF)-b-activated kinase 1
(TAK1) is a key serine/threonine protein kinase that med-
iates signals transduced by pro-inﬂammatory cytokines
such as transforming growth factor-b, tumour necrosis
factor (TNF), interleukin-1 (IL-1) and wnt family ligands.
TAK1 is found in complex with binding partners TAB1–3,
phosphorylation and ubiquitination of which has been
found to regulate TAK1 activity. In this study, we show
that TAB1 is modiﬁed with N-acetylglucosamine
(O-GlcNAc) on a single site, Ser395. With the help of a
novel O-GlcNAc site-speciﬁc antibody, we demonstrate that
O-GlcNAcylation of TAB1 is induced by IL-1 and osmotic
stress, known inducers of the TAK1 signalling cascade. By
reintroducing wild-type or an O-GlcNAc-deﬁcient mutant
TAB1 (S395A) into Tab1
 /  mouse embryonic ﬁbroblasts,
we determined that O-GlcNAcylation of TAB1 is required for
full TAK1 activation upon stimulation with IL-1/osmotic
stress, for downstream activation of nuclear factor jBa n d
ﬁnally production of IL-6 and TNFa. This is one of the ﬁrst
examples of a single O-GlcNAc site on a signalling protein
modulating a key innate immunity signalling pathway.
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Introduction
Transforming growth factor (TGF)-b-activated kinase 1
(TAK1), also known as mitogen-activated protein kinase
kinase kinase 7 (MAP3K7), is a member of the mitogen-
activated protein kinase (MAPK) family (Yamaguchi et al,
1995). TAK1 has a key role in the production of tumour
necrosis factor (TNF)a and other inﬂammatory mediators by
activating several MAPKs, such as p38a MAPK, c-Jun N-
terminal kinases (JNK1/JNK2), ERK1/2 and the transcription
factor nuclear factor kB (NFkB) (Wang et al, 2001; Sato et al,
2005; Shim et al, 2005) via the signalling pathways shown in
Figure 1A. TAK1 is essential in several cytokine-mediated
innate immunity signal transduction cascades, including the
TNFa, interleukin-1 (IL-1) and TGF-b pathways, as well as
signalling downstream of Toll-like receptors and NOD1/2
(Shibuya et al, 1996; Ninomiya-Tsuji et al, 1999; Hasegawa
et al, 2008) (Figure 1A). In these pathways, various
pro-inﬂammatory cytokines and endotoxins trigger TAK1
activity, leading to its autophosphorylation and subsequent
recruitment to the IkB kinase (IKK) complex, ultimately
resulting in activation of the transcription factor NFkB
(Adhikari et al, 2007) (Figure 1A). The native forms of
TAK1 comprise the catalytic kinase subunit in complex with
a regulatory subunit TAB1 (TAK1-binding protein 1, a pseu-
dophosphatase; Conner et al, 2006) (Figure 1B), and either of
two homologous proteins, TAB2 or TAB3 (Shibuya et al,
1996; Ishitani et al, 2003; Cheung et al, 2004). The activation
of TAK1 by lipopolysaccharide (LPS) or IL-1 is triggered by
the Lys
63-linked poly-ubiquitination of TNF receptor-asso-
ciated factor 6 (TRAF6), which binds to the C-terminal
zinc-ﬁnger motifs of TAB2 and TAB3, stimulating autopho-
sphorylation and activation of TAK1 (Wang et al, 2001).
TAK1 activity is also subject to regulation by a feedback
loop in which p38a MAPK suppresses the activation of TAK1
by phosphorylation of TAB1 at Ser423 and Thr431 (Cheung
et al, 2003). Disruption of the Tab1 gene in mice is embryonic
lethal with several developmental phenotypes, including
cardiovascular and lung dysmorphogenesis (Komatsu et al,
2002). Studies with Tab1-deﬁcient mouse embryonic ﬁbro-
blasts (Tab1
 /  MEFs) suggest that TAB1 plays several roles
in the regulation of the TAK1 complex, namely to recruit p38a
MAPK to the TAK1 complex for the phosphorylation of TAB3,
to suppress the dephosphorylation of TAB3, and to induce
TAK1 catalytic activity (Mendoza et al, 2008). TAB1 is a
crucial mediator in TAK1 signalling as Tab1
 /  MEFs do
not activate TAK1 in response to IL-1 and TNFa (Mendoza
et al, 2008). MEKK3 is maintained in an inactive state by
interaction with TAK1 in unstimulated cells, preventing basal
NFkB signalling. Pro-inﬂammatory activation of TAK1 leads
to disruption of MEKK3–TAK1 complexes via TAB1, allowing
both TAK1 and MEKK3 to transduce biochemical signals (Di
et al, 2008).
Protein glycosylation with N-acetylglucosamine (O-GlcNAcyla-
tion) is an abundant post-translational modiﬁcation of ser-
ines/threonines occurring on nuclear and cytoplasmic pro-
teins (reviewed in Love and Hanover, 2005; Hart et al, 2007).
As with phosphorylation, modiﬁcation by O-GlcNAc is dy-
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1394namic (Kreppel et al, 1997; Comer and Hart, 2000; Zachara
and Hart, 2002), giving rise to functionally distinct protein
species and there is evidence to suggest that O-GlcNAc may
show interplay with protein phosphorylation (Zeidan and
Hart, 2010). O-GlcNAcylation is implicated in virtually all
cellular processes examined, for instance gene expression
(Comer and Hart, 1999), protein turnover (Hart et al, 2007),
and also in regulating cellular responses to insulin (Vosseller
et al, 2002; Copeland et al, 2008), cell-cycle control (Slawson
et al, 2005), stress protection (Zachara et al, 2004) and
calcium cycling (Clark et al, 2003). The enzymes responsible
for the attachment (O-GlcNAc transferase, OGT) and removal
(O-GlcNAcase, OGA) of this sugar moiety have been found in
the nucleus and the cytoplasm of cells. The genes encoding
these enzymatic activities have been cloned and character-
ized (Kreppel et al, 1997; Lubas and Hanover, 2000; Gao et al,
2001). The N-terminus of OGT contains multiple tetratrico-
peptide repeats thought to mediate protein–protein interac-
tions that are critical for substrate recognition (Kreppel and
Hart, 1999; Lubas and Hanover, 2000; Clark et al, 2003).
Inactivation of the OGT gene in mouse cells has shown that
OGT is required for embryonic stem cell viability and mouse
ontogeny (Shaﬁ et al, 2000). In addition, dysfunctional
protein O-GlcNAcylation/phosphorylation appears to have a
role in the pathology of type II diabetes (Hanover et al, 1999)
and Alzheimer’s disease (Grifﬁth and Schmitz, 1995;
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Figure 1 Stimulation and activation of the TAK1 pathway and TAB1 domain structure. (A) TAK1 is a key player in the cascades of cellular
responses evoked by changes in the environment, as its activity is regulated by growth factors, pro-inﬂammatory cytokines and pathogen-
derived molecules. TAK1 activity is modulated via its binding partners TAB1 and TAB2/3, phosphorylating (denoted by P) and activating a
number of other important protein kinases; the p38a MAPK, c-jun N-terminal kinase (JNK) through MKK (MAPK kinase) and IKK complex.
Extracellular signal-regulated kinase (ERK1/2) and p38a MAPK exert their effects at the post-translational level on transcription factors (TFs),
whereas IKKb controls the transcription of genes encoding inﬂammatory mediators by regulating cellular localization of NFkB. Transcriptional
responses initiated by these pathways are of fundamental importance for the whole organism as they determine cell fate and protect cells from
pathogens and changes in osmolarity. This study shows that TAB1, a key regulator of TAK1, is also O-GlcNAcylated (denoted by G).
(B) Schematic diagram of the full-length TAB1 domain structure (amino acids, 1–504). TAB1 consisted of a PP2C-like pseudophosphatase
domain, a p38a-binding domain, and TAK1-binding domain. TAB1 is phosphorylated by p38a MAPK at Ser423 (S423) and Thr431 (T431) and
by both ERK1/2 and JNK1/2 at Ser438 (S438). This study shows that Ser395 (gS395) is the single O-GlcNAc site on the TAB1 protein.
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for O-GlcNAc modiﬁcation in the regulation of immune cells,
particularly in the activation processes of T and B-lympho-
cytes and possible increased nuclear translocation and activ-
ity of nuclear factor of activated Tcells and NFkB (Golks and
Guerini, 2008).
Here we demonstrate that O-GlcNAcylation of a single
residue (Ser395) on TAB1 modulates TAK1 activation in
response to IL-1 stimulation or osmotic stress. TAB1
O-GlcNAcylation induces a substantial increase in TAK1 auto-
phosphorylation and activation, phosphorylation of IKK,
translocation of NFkB and ultimately cytokine production.
Results
TAB1 is O-GlcNAcylated on Ser395
Many cytoplasmic and nuclear proteins such as transcription
factors, RNA polymerase II, oncoproteins, nuclear pore pro-
teins, viral proteins, and tumour suppressor proteins have
been found to be modiﬁed by O-GlcNAc at serine and
threonine residues (Hart et al, 2007; Lazarus et al, 2009).
During reanalysis of a previously reported phosphosite map-
ping study of TAB1 (Cheung et al, 2003), a peptide with an
increase in mass of 203 was observed, suggesting possible
O-GlcNAc modiﬁcation. To investigate whether TAB1 is an
O-GlcNAc modiﬁed protein, full-length TAB1 was produced
recombinantly in Escherichia coli and was O-GlcNAcylated
in vitro using recombinant human O-GlcNAc transferase
(hOGT). This resulted in a TAB1 protein species that was
recognized by the anti-O-GlcNAc antibody CTD110.6
(Figure 2A). This was further conﬁrmed using an alternative
method for O-GlcNAc detection, involving chemoenzymatic
labelling of the O-GlcNAc residue. Here, the O-GlcNAc moiety
on the protein is labelled with UDP-GalNAz using a mutant
galactosyltransferase GalT1 Y289L (mGalT1) with an azide
derivative of UDP-GalNAc (UDP-GalNAz) as donor substrate,
followed by labelling with biotin alkyne (Khidekel et al,
2003). After in vitro O-GlcNAcylation, TAB1 was subjected
to mGalT1 labelling and then detected by probing with
streptavidin-conjugated HRP (Figure 2B).
To conﬁrm TAB1 as a bona ﬁde OGT substrate with
dynamic O-GlcNAc modiﬁcation in vivo, we studied TAB1
O-GlcNAcylation in human embryonic kidney 293 (HEK293)
cells overexpressing the IL-1 receptor (IL-1R cells) treated
with/without the potent and speciﬁc OGA inhibitor
GlcNAcstatin (Dorfmueller et al, 2006). TAB1 was immuno-
precipitated from lysates and probed with the anti-O-GlcNAc
antibody CTD110.6 (Figure 2C). TAB1 possesses a basal level
of O-GlcNAcylation when grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) media containing 25mM glucose
(high glucose DMEM), increased by treatment with
GlcNAcstatin (Figure 2C). To further conﬁrm the O-GlcNAc
signal on TAB1, TAB1 immunoprecipitated from IL-1R cells
was treated with CpOGA (Rao et al, 2006), a promiscuous
bacterial OGA, which removed O-GlcNAc from TAB1 without
alteration in protein levels (Figure 2D). The O-GlcNAc signal
on TAB1 could also be blocked by competition with free
GlcNAc when the CTD110.6 antibody was pre-incubated with
500mM N-acetylglucosamine (Figure 2D).
To identify the site(s) of TAB1 O-GlcNAcylation,
recombinant O-GlcNAcylated TAB1 was analysed by mass
spectrometry. In an initial experiment, O-GlcNAcylated
TAB1 was trypsin digested and analysed by liquid chro-
matography-mass spectrometry (LC-MS). A single peptide
VYPVSVPYSSAQSTSK (amino acids 387–402) was identiﬁed
as carrying an additional molecular weight of 203. Two
parallel approaches were then employed to identify the
O-GlcNAcylation site(s) in this peptide. First, amino acids
that could be putative targets for O-GlcNAcylation (part of
PVS motif, similarity to target sequences of proline-directed
kinases (Hart et al, 1996) were mutated to alanine. A TAB1
triple mutant (S391A/S395A/S396A) or the individual TAB1
mutants S391A, S395A and S396A were expressed as GST-
tagged proteins in IL-1R cells treated with GlcNAcstatin. After
48h, these GST fusion proteins were pulled down and blotted
for O-GlcNAc. The triple mutant as well as the single S395A
TAB1 mutant showed complete absence of an O-GlcNAc
signal (Figure 2E), suggesting that S395 is the single
O-GlcNAc site on TAB1. In a parallel approach, the TAB1
O-GlcNAc site was studied by collision-induced dissociation
(CID) and electron transfer dissociation (ETD) liquid chro-
matography (LC) tandem mass spectrometry (MS/MS) ex-
periments. TAB1 was O-GlcNAcylated in vitro, trypsin
digested, and analysed by LC-MS/MS. The tryptic peptide
VYPVSVPYSSAQSTSK (Mwcalc¼1901.9Da) containing a
HexNAc (þ203.1Da) was detected after 25.5min as
[MþHexNAcþ2H]
2þ m/z 951.904. While the CID spectrum
(Figure 2F) did not fully deﬁne the site of modiﬁcation, the
ETD spectrum contained the critical fragment ions to unam-
biguously deﬁne S395 as the only O-GlcNAc modiﬁed site on
TAB1 (Figure 2G).
O-GlcNAcylation of TAB1 is inducible
As shown previously (Figure 2C), levels of O-GlcNAc on
TAB1 appear to be increased in the presence of the potent
OGA inhibitor GlcNAcstatin. We next investigated stress-
induced changes in the O-GlcNAc levels of TAB1 in wild-
type (WT) MEFs. To enable these experiments, we attempted
to generate a site-speciﬁc TAB1 S395 O-GlcNAc antibody.
Although several attempts have been made to generate such
site-speciﬁc O-GlcNAc antibodies recently, most of these still
recognize a range of O-GlcNAc proteins (Teo et al, 2010). The
only site-speciﬁc O-GlcNAc antibodies known to date are
gThr58 on c-Myc (Kamemura et al, 2002) and gSer1011 on
IRS1, gSer347 on CKII (Teo et al, 2010) and gSer400 on
Tau (Yuzwa et al, 2010). Using a classical approach, we
synthesized the TAB1-derived glycopeptide CVSVPYS
(O-GlcNAc)SAQSTSKTS, exploiting the additional N-terminal
cysteine for coupling to KLH. Serum generated from rabbits
immunized with this antigen contained antibodies that were
capable of recognizing O-GlcNAcylated TAB1, but not the O-
GlcNAc-deﬁcient TAB1 S395A mutant or the TAB1 triple
mutant (S391A/S395A/S396A) (Figure 3A). Interestingly,
while hyperglycaemic conditions resulted in an increase in
global O-GlcNAc levels and also increased O-GlcNAcylation
of TAB1 in MEFs, stimulation with IL-1 and NaCl, known to
speciﬁcally activate the TAK1 signalling pathway (Ninomiya-
Tsuji et al, 1999; Wang et al, 2001; Cheung et al, 2003;
Huangfu et al, 2006), did not raise global O-GlcNAc levels
to the same extent but still increased O-GlcNAcylation of WT
TAB1 (Figure 3B and C). This suggested that the O-
GlcNAcylation levels on TAB1 are modulated by stimuli that
are known to activate TAK1 signalling, and could perhaps
also affect signalling downstream of TAK1.
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activation
To investigate the effects of O-GlcNAcylation of TAB1 on
activation of the TAK1 kinase and downstream signalling,
we reintroduced WT TAB1 and the O-GlcNAc-deﬁcient S395A
mutant into Tab1
 /  MEFs. In untransfected Tab1
 /  MEFs,
or the cells transfected with empty plasmid, there was no
detectable IL-1a-induced TAK1 activity in agreement with
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Figure 2 TAB1 is O-GlcNAcylated on Ser395. (A)R e c o m b i n a n tT A B 1w a sO-GlcNAcylated in vitro with recombinant hOGT. The samples were
denatured in LDS (lithium dodecyl sulphate), subjected to SDS–PAGE and immunoblotted with a generic O-GlcNAc antibody CTD110.6. Total protein
was detected with a total TAB1 antibody (TAB1) as a loading control. (B) In vitro O-GlcNAcylated TAB1 was subjected to enzymatic labelling using
galactosyltransferase (mGalT1) labelling and UDP-GalNAz, before reacting with biotin alkyne for detection with HRP. The samples were denatured in
LDS, subjected to SDS–PAGE and probed with horseradish peroxidase-conjugated streptavidin (Extravidin-HRP). (C) In vivo O-GlcNAcylation of
TAB1 was detected by immunoprecipitating the endogenous TAB1 from IL-1R cells (treated with or without GlcNAcstatin—1mM) using an antibody
directed against TAB1. A non-speciﬁc IgG was included as a control. Immunoprecipitates were denatured in LDS, subjected to SDS–PAGE and
immunoblotted with generic O-GlcNAc antibody CTD110.6 and then with the TAB1 antibody for loading controls. Treating the cells with the potent
and selective OGA inhibitor GlcNAcstatin further increased TAB1 O-GlcNAcylation at a concentration of 1mM. (D) TAB1 was immunoprecipitated,
from cells treated with or without GlcNAcstatin (1mM), using the TAB1 antibody. One fraction of the reaction was treated with CpOGA for 30min at
room temperature, denatured in LDS, followed by immunoblotting with the generic O-GlcNAc antibody CTD110.6. A parallel set of immunopre-
cipitated samples were denatured in LDS and subjected to western blotting with antibody pre-incubated with N-acetylglucosamine, which blocks the
O-GlcNAc signal on TAB1. Lower panel shows the corresponding Ponceau-stained membrane before western blotting. (E) WT TAB1, the S391A/
S395A/S396ATAB1 triple mutant and the S391A, S395A and S396ATAB1 single mutants were transfected into IL-1R cells. After 24h, the cells were
treated with 1mM of GlcNAcstatin for 16h and the GSt–TAB1 was pulled out using glutathione-sepharose beads. The samples were denatured in LDS,
subjected to SDS–PAGE and immunoblotted with the generic O-GlcNAc antibody CTD110.6 and then with a total TAB1 antibody (TAB1) as a loading
control. (F, G) LC-MS/MS CID (F)a n dE T D( G) site mapping of the TAB1 O-GlcNAc modiﬁcation site. In vitro O-GlcNAcylated TAB1 was digested
with trypsin and subjected to LC–MS. The tryptic peptide VYPVSVPYSSAQSTSK (Mwcalc¼1901.9Da) containing a HexNAc (þ203.1Da) was
detected after 25.5min as [MþHexNAcþ2H]
2þ m/z 951.904. The observed fragment ions are indicated, in case of the ETD experiment allowing
deﬁnition of S395 as the site of O-GlcNAc modiﬁcation. Figure source data can be found in Supplementary data.
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transfected with WT TAB1 showed signiﬁcant recovery of
TAK1 autophosphorylation and activation (Supplementary
Figure S1A and B). To establish an optimal reconstituted
TAK1–TAB1 system, the Tab1
 /  MEFs were transfected
with varying amounts of TAB1 plasmid (pEBG GST–TAB1)
(Supplementary Figure S1C and D). Reconstituting Tab1
 / 
MEFs with 5mg of the TAB1 plasmid resulted in restoration
of TAK1 activity similar to that of Tab1
þ/þ MEFs, with TAB1
protein levels similar to endogenous TAB1 levels
(Supplementary Figure S1E and F).
To investigate the effect of TAB1 O-GlcNAcylation on TAK1
activity, reconstituted Tab1
 /  MEFs were stimulated with
IL-1a for 5 or 15min, the TAK1 complexes pulled down and
analysed for kinase activity and activatory autophosphoryla-
tion. When transfected with WT TAB1, IL-1a treatment in-
creased TAB1 O-GlcNAcylation and stimulated TAK1 activity,
as evidenced by phosphorylation of T187 in the activation loop
of TAK1 (Figure 4A and B). Strikingly, both TAK1 kinase
activity and T187 autophosphorylation were reduced with
the O-GlcNAc-deﬁcient TAB1 S395A mutant (Figure 4A and
B). To rule out the possibility TAK1 is itself O-GlcNAcylated,
thus regulating kinase activity, TAK1 O-GlcNAcylation was
investigated. GST–TAK1 and GST–TAB1 were co-expressed in
IL-1R cells maintained in 1g/l glucose DMEM (low glucose
DMEM). Cells were either treated with GlcNAcstatin or stimu-
lated with IL-1b or NaCl before GST pulldowns and probing for
O-GlcNAcylation. As expected, TAB1 was O-GlcNAcylated in
the presence of higher glucose conditions or on stimulation
with IL-1 or NaCl, whereas TAK1 was not, suggesting that
under physiological conditions as well as in stimulated condi-
tions TAK1 is not O-GlcNAc modiﬁed (Supplementary Figure
S2). Furthermore, the AK1–TAB1 complex remains intact in
these experiments (Supplementary Figure S2).
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Figure 3 O-GlcNAcylation of TAB1 is modulated in response to IL-1 or NaCl stimulation. (A) The TAB1-derived glycopeptide CVSVPYS(O-
GlcNAc)SAQSTSKTS, was used to generate an O-GlcNAc site-speciﬁc polyclonal antibody against O-GlcNAc S395. The speciﬁcity of the
antibody was determined using cell lysates prepared from IL-1R cells transfected with WT TAB1, S395A TAB1 and the S391A/S395A/S396A
TAB1 triple mutant and treated with or without GlcNAcstatin (1mM). The cell lysates were denatured in LDS, subjected to SDS–PAGE and
immunoblotted with the site-speciﬁc polyclonal antibody against O-GlcNAc S395. The antibody recognized the signal in WTsamples only with
increased signal intensity when O-GlcNAcylation of TAB1 is increased by GlcNAcstatin treatment. (B) Tab1
þ/þ MEFs cells were (i) maintained
in hyperglycaemic conditions (25mM glucose) or (ii) treated with GlcNAcstatin (1mM) or (iii) subjected to stress by treatment with IL-1a
(10ng/ml) or 100mM of NaCl for 6h under low glucose conditions (5mM). Cell extracts (30mg protein) were denatured in LDS, subjected to
SDS–PAGE and immunoblotted with O-GlcNAc (CTD110.6) antibody and b-tubulin antibody for loading control. (C) The samples from (B) were
probed simultaneously using the site-speciﬁc TAB1 O-GlcNAc S395 antibody (gS395). Figure source data can be found in Supplementary data.
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to the cytosol along with TRAF6 and its binding partners,
TAB1 and TAB2/3. TAK1 activation subsequently leads to
activation of IKK and c-Jun NH2-terminal kinase (JNK) as
well as p38a MAPK. Activated IKK phosphorylates IkB
proteins, and phosphorylated IkB proteins are degraded by
the ubiquitin-mediated proteasome pathway (Karin and Ben-
Neriah, 2000). To investigate the effects of TAB1 O-GlcNAcylation
on these downstream events, we investigated Ikba phosphoryla-
tion. In line with reduced TAK1 activation, IL-1a-stimulated
phosphorylation of Ikba Ser32 and Ser36 was reduced by up to
50% in the Tab1
 /  MEFs expressing S395A TAB1 as compared
with WT TAB1 (Figure 4C and D). Phosphorylation of p38a
MAPK or ERK1 was not affected with the S395A mutant
(Supplementary Figure S3). Previous work has shown that
TAK1 activation can also be robustly induced by osmotic stress,
independent of stimulation with cytokines/LPS, leading to down-
stream activation of JNK1/2 (Inagaki et al, 2008). Indeed,
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Figure 4 O-GlcNAcylation of TAB1 affects activation of TAK1 and phosphorylation of its downstream targets IkBa and JNK1/2. (A) IL-1a or
NaCl-induced activation of TAK1 in WTand S395ATAB1 transfected Tab1
 /  MEFs. At 36h post-transfection, MEFs were serum starved for 6h,
and then stimulated for 5 and 15min with 10ng/ml IL-1a or 0.5M NaCl. The TAK1 complexes were pulled down from the cell extracts (1mg of
protein extract) using glutathione-sepharose beads, and TAK1 activity assays were performed (as described in the Materials and methods
section) in addition to immunoblotting as described below in (B). The data are expressed as the relative increase in TAK1 activity of the IL-1/
NaCl-stimulated samples compared with the basal activity of the unstimulated control samples. Error bars denote standard deviation,
determined from three independent experiments. (B) In parallel to the experiments in (A), TAK1 complexes were denatured in LDS, subjected
to SDS–PAGE and immunoblotted with a phospho-speciﬁc antibody that recognizes TAK1 autophosphorylation at Thr187 (pT187) and with a
further antibody that recognizes all forms of TAK1. O-GlcNAcylation of TAB1 was detected with the site-speciﬁc O-GlcNAc antibody (gS395)
versus a total TAB1 antibody control (TAB1). (C) In all, 30mg of the cell lysates from the samples obtained as in (A) was immunoblotted for
phosphorylated Ikba p-Ikba and total Ikba.( D) Densitometry for IkBa phosphorylation after normalization against total TAB1 levels. The data
shown are the average of three independent experiments with error bars denoting standard deviation. (E) WTand S395ATAB1 were transfected
in Tab1
 /  MEFs. At 36h post-transfection, MEFs were serum starved for 6h, and then stimulated for 5 or 15min with 0.5M NaCl. The TAK1
complexes were pulled down from the cell extracts (1mg of protein extract) using glutathione-sepharose beads and taken for kinase assays (A)
in addition to immunoblotting. For immunoblotting, the samples were denatured in LDS, subjected to SDS–PAGE and immunoblotted with a
phospho-speciﬁc antibody that recognizes TAK1 autophosphorylation at Thr187 (pT187) and with a further antibody that recognizes all forms
of TAK1. O-GlcNAcylation of TAB1 was detected with the site-speciﬁc O-GlcNAc antibody (gS395) versus a total TAB1 antibody control (TAB1).
(F) In all, 30mg of the cell lysates from the samples obtained as in (E) was immunoblotted for phosphorylated JNK1/2 (p-JNK1/2) and total
JNK1/2. (G) Densitometry for JNK1/2 phosphorylation after normalization for total JNK1/2. The data shown are the average of minimum of
three independent experiments with error bars denoting standard deviation. Figure source data can be found in Supplementary data.
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ylation of TAK1 T187, and in parallel O-GlcNAcylation of TAB1
S395, in the Tab1
 /  MEFs complemented with WT TAB1
(Figure 4A and E). This effect was reduced with the O-GlcNAc-
deﬁcient TAB1 S395A mutant (Figure 4A and E), which also
translated into reduced phosphorylation of JNK1/2 on Thr183
and Tyr185 (Figure 4F and G).
O-GlcNAcylation of TAB1 modulates NFjB activation
and IL-1a-stimulated cytokine release
In the canonical NFkB activation pathway, upon phosphor-
ylation by IKKb,I kba and IkBb, the cytoplasmic inhibitors of
NFkB, are marked for ubiquitination and subsequent
proteosomal degradation (DiDonato et al, 1996; Ghosh and
Karin, 2002). The degradation of IkBa and IkBb allows
translocation of NFkB to the nucleus, leading to transcription
of a plethora of genes including those encoding various
cytokines (Li and Verma, 2002; Hayden and Ghosh, 2008).
Using a reporter assay, we studied the role of O-GlcNAc
on TAK1/TAB1-mediated activation of NFkB in response to
IL-1a stimulation in Tab1
 /  MEFs overexpressing WT or
S395A TAB1 (Figure 5). While a robust level of NFkB activa-
tion was observed with WT TAB1, S395A TAB1 showed a
signiﬁcant reduction in NFkB activation (Figure 5A), in line
with the observed reduction in phosphorylation of IkBa
(Figure 4C). To evaluate whether the observed reduction in
NFkB activity of the TAB1 S395A mutant resulted in effects
on cytokine production, levels of IL-6 and TNFa cytokines
were measured in the cell culture medium at different time
points after IL-1a stimulation. IL-6 secretion was reduced by
50% after 8h and 40% after 24h in samples from the cells
transfected with the S395A TAB1 mutant, as compared with
the WT TAB1 control (Figure 5B). Similarly, TNFa produc-
tion, 8 and 16h after IL-1a stimulation, was signiﬁcantly
reduced with the O-GlcNAc-deﬁcient TAB1 mutant
(Figure 5C).
O-GlcNAcylation of TAB1 modulates regulatory
phosphorylation
TAB1 possesses three characterized phosphorylation sites
(S423, T431 and S438) that are modiﬁed under various
stimuli and are involved in TAK1 activation (Mendoza et al,
2008) (Figure 1A and B). p38a MAPK phosphorylates S423
and T431 whereas ERK1/2 and JNK1/2 phosphorylate S438
(Mendoza et al, 2008), although the speciﬁc roles of the
individual phosphorylation sites have not yet been deﬁned.
The regulatory TAB1 O-GlcNAc site described here does not
correspond to a known phosphorylation site; however, it is in
proximity to the phosphorylation sites and the C-terminal
region of TAB1 that is required for interaction with TAK1
(Ono et al, 2001) (Figure 1B). To investigate possible effects
of O-GlcNAcylation of TAB1 on phosphorylation at S423,
T431 and S438, Tab1
 /  MEFs transiently transfected with
TAB1 (WTand S395A) were stimulated with sodium chloride
in the presence or absence of GlcNAcstatin. When stimulated
with NaCl, phosphorylation of S438 was observed to increase
in both WT and S395A TAB1 mutant when compared with
control. However, in the presence of both NaCl and
GlcNAstatin, there is a further increase in phosphorylation
of S438 in WT, but this further increase was not seen in the
S395A mutant. This suggests that O-GlcNAc at S395 may
regulate TAB1 phosphorylation at S438.
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Figure 5 TAB1 O-GlcNAcylation affects NFkB-dependent gene tran-
scription and cytokine production. (A) Tab1
 /  MEFs were co-
transfected with either WT TAB1, S395A TAB1 or empty plasmid
and plasmids encoding the 3 kB luciferase reporter construct;
and pRL-TK. After 24h of transfection, the cells were stimulated
with 10ng/ml of IL-1a for 24h before lysing with Passive
Lysis Buffer (Promega). NFkB-dependent luciferase reporter gene
expression was measured and normalized for transfection efﬁciency
using Renilla luciferase as the internal control. The data are
presented as background-corrected mean values±s.e.m. from
three to four independent experiments. (*) denotes Po0.05 for
signiﬁcant differences between mutant and WT TAB1. (B, C) Tab1
 / 
MEFs were transfected with WT or S395A TAB1 plasmid and 24h
post-transfection stimulated with 10ng/ml IL-1a for 8–24h. The
media was collected and the quantiﬁcation of (B) IL-6 and (C) TNFa
was performed by ELISA. The data are presented as background-
corrected mean values±s.e.m. from three to four independent
experiments. (*) denotes Po0.05 for signiﬁcant differences between
mutant and WT TAB1.
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in the presence of both GlcNAcstatin and NaCl as compared
with the S395A mutant, while there was no change on
S423 or T431 phosphorylation (Figure 6). S438 is phosphory-
lated by ERK1/2 and JNK1/2, and TAB1 has a role in
stress response and activation of JNK1/2 pathway (Inagaki
et al, 2008). The reduced phosphorylation at S438 on S395A
TAB1 as compared with that of WT TAB1 could be related to
the reduced activation of JNK1/2 as observed earlier,
although its not yet clear how TAB1 O-GlcNAcylation may
regulate JNK1/2 activity towards the TAB1 S438 phosphor-
ylation site.
Discussion
TAK1 is a key regulator of NFkB activity and cytokine
production in response to stimulation with LPS and
cytokines. Over the past decade, a large number of studies
have shown that TAK1 activity is extensively regulated by
phosphorylation, ubiquitination, and binding to the regula-
tory binding partners TAB1–3 (Sakurai et al, 2000; Wang et al,
2001; Ishitani et al, 2003; Ea et al, 2004; Singhirunnusorn
et al, 2005). The data presented here show that TAB1
possesses a single, inducible O-GlcNAc site, Ser395 that is
responsive to IL-1 and NaCl, known activators of the TAK1
pathway. By reintroducing WT TAB1 or an O-GlcNAc-
deﬁcient mutant in Tab1
 /  MEFs, we were able to delineate
the role of O-GlcNAcylation of TAB1. With IL-1 stimulation,
TAB1 O-GlcNAcylation enhances Ikba phosphorylation,
which in turn regulates NFkB activation. We show here that
O-GlcNAcylation of TAB1 is required for full activation of
TAK1 on Thr187 and that there is a direct correlation between
O-GlcNAcylation of TAB1, autophosphorylation of TAK1
Thr187, activation of NFkB and, ultimately, production of
IL-6 and TNFa.
Recent studies have shown effects of hyperglycaemia on
the transcriptional activity of NFkB and also on IKkb,k e y
regulators of innate immunity pathways. Both IKKb and
NFkB are also O-GlcNAc modiﬁed proteins (Yang et al,
2008; Kawauchi et al, 2009). Taken together with the data
presented here, this suggests that the innate immune
response is not only regulated by phosphorylation and ubi-
quitination but also by O-GlcNAcylation. Further work will
be required to understand how O-GlcNAcylation of TAB1 is
induced/regulated, and also to unravel the molecular details
of O-GlcNAc-dependent TAK1 activation by TAB1.
Materials and methods
Materials
GlcNAcstatin was obtained from GlycoBioChem (Dundee, UK). Mouse
IL-6 and TNFa Elisa kits were purchased from Peprotech, UK. Human
IL-1b was from Sigma, murine IL-1a was from Peprotech and
glutathione-sepharose was from GE Healthcare. Luciferase reporter
assay kit was from Promega. Click-iTTM O-GlcNAc Enzymatic Labeling
System and Click-iT Biotin Glycoprotein Detection Kit were from
Invitrogen. Dynabeadss Protein G was from Invitrogen.
DNA cloning
Full-length TAB1 was cloned and inserted into pGEX6P1 for
recombinant protein production in E. coli and pEBG6P for transfection
in mammalian cells, as described previously (Cheung et al, 2004).
Mutations for putative O-GlcNAc sites on TAB1 (S391A, S395A and
S396A) were created following the Quick Change method (Stratagene)
using KOD Hot start Polymerase (Novagen). Recombinant OGT was
produced as described previously (Clarke et al, 2008). GST–TAK1 was
obtained from the Division of Signal Transduction Therapy DSTT in
Dundee. CpOGA was produced as described previously (Rao et al,
2006). For NFkB reporter assays, DNA encoding a ConA basal
promoter incorporatingt h r e ec o p i e so ft h eN F kB DNA response
element (termed ‘3  kB luciferase reporter construct’) was provided
by Professor Ron Hay, College of Life Sciences, University of Dundee
(Rodriguez et al, 1999). The pRL-TK vector driving Renilla luciferase
expression was from Promega.
Antibodies
The antibodies that recognize TAK1 phosphorylated at Thr187, total
TAB1, TAB1 phosphorylated at Ser423 and TAB1 phosphorylated
at Ser438 were used as described previously (Cheung et al, 2003).
Antibodies recognizing the active phosphorylated forms of ERK1/2,
JNK1/2, p38a MAPK and total ERK1/2, JNK1/2 were from Cell
Signalling Technologies. ExtrAvidins-Peroxidase was from Sigma.
For immunoblotting with the phospho-speciﬁc antibodies for TAK1
and TAB1, the antibodies were incubated at 3mg/ml in the presence
of 30mg/ml of the unphosphorylated peptide immunogen to
neutralize any antibodies that recognize the unphosphorylated
form of the protein. The anti-O-GlcNAc antibody CTD110.6 was
purchased from Abcam. Secondary antibodies conjugated to
horseradish peroxidase were from Pierce.
Generation of O-GlcNAc-speciﬁc antibody against S395 on TAB1
The O-GlcNAc peptide CVSVPYS(O-GlcNAc)SAQSTSKTS, correspond-
ing to residues 389–403 of TAB1, was synthesized on a Liberty
microwave-assisted peptide synthesizer (CEM) using MBHA Rink-
amide low load resin (Novabiochem) with standard protocols of Fmoc
SPS chemistry. The QS dipeptide was introduced as pseudoproline to
suppress formation of truncated sequences detected in pilot experi-
ments. 4Ac-GlcNAcSerFmoc was synthesized in-house following a
published procedure (Saha and Schmidt, 1997). After high peformance
liquid chromatograpy (HPLC) puriﬁcation of the peptide, it was
conjugated to keyhole limpet haemocyanin and injected into rabbits.
Antibodies from the serum were ﬁrst precipitated with ammonium
sulphate followed by a one-step puriﬁcation by passing the resuspended
antibody over a non-GlcNAcylated peptide column. The ﬂowthrough
from the column was collected and used for immunoblotting.
In vitro O-GlcNAc assay
In vitro o-GlcNAcylation of TAB1 (1mM) was performed in 20ml
assay volumes containing 100nM of OGT, reaction buffer (50mM
Tris–HCl, pH 7.5, 1mM DTT, 12.5mM MgCl2), and 1mM UDP-
GlcNAc. The reactions were incubated for 90min at 371C, stopped
by adding 4  SDS–PAGE sample buffer, resolved on SDS–PAGE,
transferred to PVDF and probed with appropriate antibodies.
WT S395A
TAB1
–– +
–– – – ++
++ + N a C l
GlcNacstatin
TAB1 pS438
TAB1 pT431
TAB1 pS423
TAB1 gS395
Figure 6 Interplay between TAB1 O-GlcNAcylation and phosphor-
ylation. Tab1
 /  MEFs were transfected with WT or S395A TAB1
plasmids. At 36h post-transfection, MEFs were serum starved for
6h with or without GlcNAcstatin (1mM) and then stimulated for
15min with 0.5M NaCl. Aliquots of cell extract (30mg protein) were
denatured in LDS, subjected to SDS–PAGE and immunoblotted with
antibodies that recognize TAB1 phosphorylated at Ser423 (pS423),
Thr431 (pT431) and Ser438 (pS438) and for O-GlcNAcylation at
Ser395 (gS395). Data presented are representative of results
obtained from three independent experiments. Figure source data
can be found in Supplementary data.
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GST–TAB1 was bound to glutathione-sepharose beads and was
O-GlcNAcylated in vitro. The beads were washed with 10mM
HEPES (pH 7.9) and resuspended in reaction buffer (1% SDS,
20mM HEPES) then 2ml of GalT1 Y289L (Invitrogen) and 2mlo f
0.5mM UDP-GalNAz (Invitrogen) were added in a ﬁnal reaction
volume of 50ml. The reaction was performed overnight at 41C. The
beads were washed twice with reaction buffer to remove excess
UDP-GalNAz. The samples were then reacted with biotin alkyne
(Invitrogen) according to the manufacturer’s instructions. The
proteins were resolved by SDS–PAGE and transferred to PVDF. The
blot was incubated with ExtrAvidin-Peroxidase and biotinylated
TAB1 was visualized by ECL reaction.
O-GlcNAc site mapping of TAB1
For site mapping analysis of digested TAB1 protein, an Ultimate
3000RSLC nano-HPLC system (Dionex) with a 3D high capacity ion
trap mass spectrometer with ETD capability (amaZon ETD; Bruker
Daltonics) were used to perform HPLC electrospray MS/MS (ESI-MS/
MS). Digested TAB1 samples were reconstituted in 0.1% formic acid,
injected and concentrated onto a Dionex PepMap C18 nano-trap
column, after a wash step with (2% acetonitrile, 0.1% formic acid (v/
v)) peptides were resolved by a Dionex Acclaim PepMap C18 reverse
phase column (75mmi . d . 15cm 2mm) over a 25-min linear
gradient from 4% to 50% buffer B (80% acetonitrile and 0.08% formic
acid in Milli-Q water (v/v)), followed by another 2min to 90% buffer
B. The column was then washed by holding the 90% buffer B for
10min before returning to initial conditions of 96% buffer A (0.1%
formic acid in Milli-Q water (v/v)). A typical tandem mass spectro-
metric (MS/MS) cycle (Alternating CID/ETD) in amaZon ETD happens
in the following order: (A) 1MS full-range scan and precursor ion
selection. (B) Accumulation of precursor ion (B10ms) and fragmenta-
tion by CID. (C) (CID-MS/MS spectrum recorded) accumulation of the
same precursor ion (B5ms), which is allowed to mix and react with
ﬂuoranthene (50–100ms; variable) for ETD fragmentation, and ETD-
MS/MS spectrum acquired. Steps (B) and (C) are repeated auto-
matically for each precursor ion. In this study, precursor ion selection
was set up to ﬁve ions per cycle, excluding singly charged ions, with a
dynamic exclusion time of 0.5min for both CID and ETD. Helium gas
was used as collision gas (60–200%), collision energy sweep with
amplitude 1.0 parameters was used for CID fragmentation. For ETD
experiments, the maximum output of ETD reagent ion (202 m/z)w a s
achieved with the following nCI source tuned parameters: reagent ion
charge control target (ICC) 500000, maximum emission current 4mA
and ionization energy of 75eV, reactant remove cutoff p210 m/z
without supplemental energy activation.
Raw MS data were processed using software packages BioTool
3.2 SR1 and DataAnalysis 4.0 (Bruker Daltonic GMBH). In parallel,
two database searches were performed for CID and ETD using
Mascot v2.3 (Matrix Science Ltd), database used IPI-human
20110731 (91522 sequences; 36630302 residues) with the following
Mascot MS/MS ion search parameters: peptide charges considered
2þ,3 þ and 4þ ions, peptide tolerance and fragment tolerance
was set to ±0.5Da, # of
13C¼1, two missed cleavages allowed,
trypsin as proteolysis enzyme, ESI-TRAP (for CID) and ETD-TRAP
(for ETD) for instrument type. Carbamidomethyl (C) was used as
ﬁxed modiﬁcation, where Deamidated (NQ), Oxidation (M),
Phospho (ST) and HexNAc (ST) (þ203.0794Da) were set as
variable modiﬁcations.
Cell culture, stimulation and lysis
IL-1R cells HEK293 (cells stably expressing the IL-1 receptor) and
immortalized Tab1-deﬁcient MEFs (Tab1
 /  MEFs) were provided by
Professor Philip Cohen, MRC Unit, University of Dundee. Cells were
cultured in DMEM with 1 or 4.5mg/ml glucose, containing 10% (v/v)
heat inactivated fetal calf serum (FCS), and 2mM L-glutamine. Prior to
stimulation with human IL-1b in IL-1R cells or murine IL-1a in mouse
cells, the medium was removed and replaced with DMEM from which
FCS had been omitted. IL-1R cells were serum deprived for 16h and
MEFs for 6h. GlcNAcstatin (1mM )w a sa d d e dt oc e l l sd u r i n gs e r u m
starvation, if required. For osmotic shock, cells were treated with
either 0.25 or 0.5M of NaCl by adding it into DMEM for 15min before
harvesting the cells.
Cells were lysed in ice-cold lysis buffer (50mM Tris–HCl pH 7.5,
1mM sodium orthovanadate 1mM EDTA, 10mM sodium b-
glycerophosphate, 1mM EGTA, 50mM sodium ﬂuoride, 5mM
sodium pyrophosphate, 1% (v/v) Triton X-100, 0.27M sucrose,
0.1% (v/v) 2-mercaptoethanol, 0.1mM PMSF, 1mM benzamidine
and 5mM leupeptin). Lysates were centrifuged at 13000g for 15min
at 41C and the supernatants were used immediately or snap frozen
in liquid nitrogen and stored in aliquots at  801C until use. Protein
concentrations were determined using the Bradford assay.
Immunoprecipitation and OGA treatment of TAB1
To immunoprecipitate endogenous TAB1, 1mg of cell lysate was
incubated for 2h at 41C with 10mg of anti-TAB1 antibody coupled
with 10ml of Dynabeads Protein G. The immunoprecipitates were
washed twice with 1ml of lysis buffer containing 0.25M NaCl,
followed by two washes with 1ml of 50mM Tris/HCl, pH 7.5,
50mM NaCl and 0.1 % (v/v) 2-mercaptoethanol and subjected to
SDS–PAGE followed by western blotting.
For OGA treatment on immunoprecipitated O-GlcNAcylated
TAB1, 3mg of lysate was used for immunoprecipitation. The
samples were divided in three equal volumes. One set of samples
was treated with CpOGA (1mM) for 30min at room temperature,
while the other two sets were left untreated at room temperature.
The samples were subjected to SDS–PAGE and western blotting
with CTD110.6 antibody. The third set of samples was incubated
with CTD110.6 antibody, which was pre-incubated with 500mM
N-acetylglucosamine for 1h.
Cell transfections
IL-1R cells were transfected at 40–50% conﬂuence using poly-
ethyleneimine using DNA encoding GST (glutathione transferase)–
TAB1, whereas MEFs were transfected at a density of 3 10
6 cells,
with the Amaxa MEF2 kit according to the manufacturer’s
instructions.
NFjB reporter gene assay
For the measurement of NFkB-dependent luciferase gene expression,
Tab1
 /  MEFs (3 10
6) were co-transfected with either 3mgo fW T
TAB1, S395ATAB1 or empty pEBG6 plasmid; 0.5mgo fD N Ae n c o d i n g
the 3 kB luciferase reporter construct; and 0.5mg pRL-TK and plated
3 10
5 cells per well. After 24h, the cells were stimulated with 10ng/
ml of IL-1a for 24h and then the cells were lysed in Passive Lysis
Buffer (Promega). The luciferase activity was then measured using a
Dual-Luciferase Reporter Assay System (Promega) as per the
manufacturer’s instructions. Fireﬂy luciferase activity was normalized
by Renilla luciferase activity for each transfection.
TAK1 activity assays
TAK1 present in TAB1 immunoprecipitates was assayed by its ability
to activate MKK6, as judged by the activation of SAPK2a/p38a.T h e
active SAPK2a/p38a generated in this ﬁrst stage of assay was then
quantitated in a second assay by measuring phosphorylation of myelin
basic protein (Cheung et al, 2003). The TAK1 complexes were pulled
down from 1mg of cell lysate obtained from TAB1 reconstituted MEFs.
The cell lysates were incubated for 2h at 41Cw i t h2 0ml of glutathione-
sepharose beads per sample. The beads were washed twice with 1ml
of lysis buffer containing 0.25M NaCl, followed by two washes with
high salt wash buffer (1ml of 50mM Tris–HCl pH 7.5, 0.5M NaCl and
0.1% (v/v) 2-mercaptoethanol). In all, 25% of the TAK1 complex
bound to the beads was used to measure TAK1 activity. The remaining
75% of the TAK1 complex was taken for immunoblotting using
appropriate antibodies as described earlier.
Cytokine secretion assay
For measuring TNFa and IL-6 secretion into the medium, 3 10
6
MEFs were transfected with the WTor S395ATAB1 and were seeded
in 24-well plates at density of 3 10
5cells/well. At 24h after
transfection, the cells were stimulated with IL-1a for different
lengths of time. The media were collected and after brief
centrifugation, 100ml of clear media was used for cytokine ELISA
as per the protocol from Peprotech.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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